Introduction
Compounds with quinone structure that have played a prominent role in cancer chemotherapy include the anthracyclnine quinones such as doxorubicin, daunorubicin, mitoxantrone, and mitomycin C. 1 The vitamin K family contains both natural and synthetic forms, the former including phytonadione (VK1) and the menaquinone series (VK2), and the latter including menadione (VK3). The physiological function of natural K vitamins is to act as cofactors for ␥-carboxylase, which catalyses the carboxylation of glutamates at the N-termini of prothrombin and the vitamin K-dependent coagulation factors. 2 The vitamin K family of molecules shares a common chemical structure consisting of a naphthoquinone nucleus, which involved reduction of oxidation (redox) cycling. VK1 has a long phytol side chain and VK2 has an unsaturated side chain composed of four to 13 isoprene units (polyprenylalcohols), whereas VK3 lacks the side chain.
3 VK3 has been reported to exhibit in vitro cell growth inhibitory effects in murine and human tumor cell lines, including hepatocellular carcinoma, breast carcinoma and renal cell carcinoma, [4] [5] [6] [7] which appear to be mediated in part through free radical production and DNA strand scission damage. 8, 9 In addition, polyprenylalcohols such as geranylgeraniol and geranylfarnesol, which consist of a side chain of menaquinone (MK) 4 and MK5, respectively, have been reported to induce apoptosis of tumor cell lines. 10 We originally reported that VK2 analogs such as menaquinone (MK) -3, -4, and -5, but not vitamin K1, effectively induce apoptosis in various types of primary cultured leukemia cells and leukemia cell lines in vitro. 3 This apoptosis induction was more potent than those of geranylgeraniol and geranylfarnesol in leukemia cell lines at an equivalent concentration. 3 In addition, up-modulation of BAX and downmodulation of BCL-2 expressions were observed in a VK2-treated MDS-KZ cell line, a MDS cell line which undergoes apoptosis in response to VK2. 11 Although VK1 and VK2 share the naphthoquinone nucleus, only VK2 causes programmed cell death. 3 Therefore, both a polyprenylalcohol and a naphthoquinone nucleus may thus be required for maximal apoptotic efficacy. However, in contrast to apoptosis induction in leukemia cells, it has been reported that VK2 showed some differentiation-inducing activity in acute myeloid leukemia cell lines, such as HL-60 and U937 in vitro. 12 The reason for the discrepancy between apoptosis-and differentiationinductions in response to VK2 has not been clarified.
Several recent case reports suggest the clinical benefit of using VK2 (MK4) for the treatment of patients with acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). [13] [14] [15] In patients with MDS of refractory anemia of excess of blasts in transformation (RAEB-T) and post-MDS AML (a secondary AML arising from MDS), 16 VK2 has been reported to have an effect in the reduction of blast cell numbers and improvement of cytopenia without any adverse effects. 13, 14 These data appear to be consistent with our in vitro observations showing that VK2 selectively induces apoptosis of blastic populations in the bone marrow cells of patients with refractory anemia of excess of blasts (RAEB), RAEB-T and AML. 17 However, VK2 therapy has also been reported to show the improvement of cytopenias in patients with refractory anemias (RA). 14, 15 This might be interpreted as either the differentiation-inducing effect or the elimination of the MDS clone by VK2 treatment.
In the present study, we compared the effects of VK2 in a BCL-2 over-expressed HL-60 cell line by bcl-2 gene transfection (HL-60-bcl-2) and with control HL-60-neo cells. Our data clearly demonstrate that VK2 shows not only apoptosisinducing effects, but also differentiation-inducing effects via the induction of G0/G1 arrest, especially in leukemia cells which are resistant to VK2-inducing apoptosis.
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Materials and methods
Reagents and antibodies
Menaquinone-4 (MK4) was synthesized and supplied by Eisai Chemical (Tokyo, Japan). Murine anti-human p21WAF1/CIP1 and p27KIP1 monoclonal antibodies (mAbs) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), fluorescein isothiocyanate (FITC)-conjugated human CD11b, CD13, CD14, CD15, CD16, and CD33 mAbs were purchased from DAKO (Glostrup, Denmark), and phycoerythrin (PE)-conjugated anti-human CD34 mAb was purchased from Beckon Dickinson (San Jose, CA, USA). Murine anti-human BCL-2 mAb and phycoerythrin cyanine 5 (PC-5)-conjugated APO2.7 mAb were obtained from Immunotech (Marseille, France). 18 Cell culture and transfection of bcl-2 gene HL-60 cells obtained from the American Type Culture Collection (Rockville, MD, USA) were maintained in continuous culture in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 10% FCS (Hyclone, Logan, UT, USA), 2 m l-glutamine, penicillin (50 U/ml) and streptomycin (100 g/ml). Then the cells were transfected with the recombinant pcDNA3-plasmid-containing bcl-2a gene using the electroporation method. The selection with 400 g/ml G418 (GIBCO) was started 2 days after transfection. From the pool of transfectants, the clones with high expression of BCL-2, assessed by immunoblotting were isolated by limiting dilution, and maintained in medium containing 400 g/ml G418.
Immunoblotting for detection of BCL-2
Immunoblotting with murine anti-human BCL-2 mAb was performed by the methods listed in another report. 19 
Flow cytometric analysis
Cellular antigens and viable cell number were analyzed by flow cytometry. Before staining, cells were preincubated with heat-inactivated human AB serum for 30 min at room temperature to block antibody binding to Fc receptor. Thereafter, cells were washed twice with PBS containing 0.02% NaN 3 and were incubated with FITC-or PE-conjugated monoclonal antibodies for 30 min at 4°C. For detection of p21CIP1 and p27KIP1 expressions, HL-60 cells (1 × 10 6 cells/ml) were washed twice with PBS, permeabilized with PBS containing 100 g/ml digitonin (Sigma Chemical, St Louis, MO, USA), 0.01% NaN 3 , and 2.5% FCS for 30 min at 4°C, then stained with murine anti-human p21CIP1or p27KIP1 mAb for 30 min at 4°C. After that, the cells were washed with PBS and incubated with FITC-conjugated goat anti-murine IgG (DAKO) for 30 min at 4°C. After washing twice with PBS, fluorescent intensities were analyzed by flow cytometry using EPICS XL II (Beckman-Coulter Japan, Tokyo, Japan).
For the assessment of the viable cell count, HL-60 cells treated with/without VK2 were stained with a solution containing 1% (v/v) propiodium iodide (PI) (Sigma) for 30 min at 4°C. First, the gating area of a cytogram for detecting viable HL-60 cells was established according to the PI stainingnegative area (indicating viable cells), and the forward and side scatter intensities for HL-60 cells were established by multi-color analysis. Then the cell cultures were pipetted gently to obtain uniform cell suspension, and were introduced to a flow cytometer. The number of cells in the gating area for viable HL-60 cells was assessed for 60 s. The number relative to the cells treated with a control medium correlated with the results obtained from a Cell Counting Kit (Dojin East, Tokyo, Japan), with absorption measurements at 450 nm (data not shown).
Assessment of apoptosis
The cells undergoing apoptosis were assessed by both morphology and flow cytometry using APO2.7 mAb. For morphologic observation, the cell suspension was introduced to Shandon Cytospin II (Shandon, Pittsburgh, PA, USA) and preparations were stained with May-Grü nwald-Giemsa. For flow cytometry, PC5-conjugated APO2.7 mAb (clone 2.7; Immunotech, Marseille, France), which was raised against the 38 kDa mitochondrial membrane protein (7A6 antigen) specifically expressed by cells undergoing apoptosis, 18, 20 was used. We have already reported that detection of the percentage of APO2.7-positive cells was consistent with the results of the TUNEL method and DNA ladder formation by 2% agarose gel electrophoresis in a limiting dilution system using apoptotic cells and non-apoptosis cells. 17 
Mitochondrial membrane potential
Mitochondrial membrane potential was measured by the lipophilic cationic probe JC-1 (Molecular Probes, Eugene, OR, USA) as previously reported. 21 Cells adjusted to a density of 5 × 10 5 cells/ml were incubated in complete medium containing 10 g/ml JC-1 for 20 min at room temperature in the dark. Then, the cells were washed twice in ice cold PBS, and analyzed by flow cytometry.
Assays for caspase-3 activity
Caspase-3 activity was examined by using a substrate reagent kit which contained PhiPhiLUx-G6D2, a rhodamine-containing specific substrate with amino acid sequence GDEVDGI (Oncolmmunin, College Park, MD, USA). After treatment with/without MK4, cells were washed with PBS and incubated with a substrate reagent at 37°C for 60 min. Fluorescence of the profluorescent substrate cleaved by activated caspase-3 was analyzed by flow cytometry at the FL2 channel with excitation at 488 nm.
Cell cycle analysis
Cells were fixed and stained in a solution containing 1% propidium iodide (v/v, Sigma), 100 g/ml digitonin, 0.01% NaN 3 , 200 g/ml RNAase (Sigma) and 2.5% FCS for 10 min at room temperature. Cells were analyzed by flow cytometry, and the populations of each G0/G1, S, and G2/M phases were calculated with a cell cycle analysis program, MultiCycle AV (Phoenix Flow Systems, San Diego, CA, USA).
Assessment for cell differentiation
Differentiation of HL-60 cells was assessed by morphology stained with May-Grü nwald-Giemsa and cell surface antigen expressions using flow cytometry as describe above. When assessing for monocytic differentiation, non-specific esterase staining was further performed using an esterase staining kit (Mutoh Chem, Tokyo, Japan).
Statistics
Data are given as the mean ± s.d. Comparisons between two groups were assessed with a Student's t-test.
Results
Overexpression of BCL-2 protein abolished VK2-induced apoptosis in HL-60 cells
We have reported that treating the primary cultured leukemia cells and leukemia cell lines with 1-10 m of MK4 for 48 to 72 h induces apoptosis in vitro. 3 In this study, we first focused on the influence of BCL-2 expression in leukemia cells on the apoptosis induction of VK2.
Immunoblotting with anti-BCL-2 mAb revealed that a stable transfectant clone, HL-60-bcl-2 cells expressed five-fold BCL-2 protein as compared with HL-60-neo cells (Figure 1a ). There was no difference regarding growth speed, morphology, and antigen expressions among parental HL-60, HL-60-neo, and HL-60-bcl-2 cells (data not shown). Next, HL-60-neo and HL-60-bcl-2 cells were cultured in the presence of various concentrations of VK2 (MK4) for 72 h. Thereafter, the viable cell number was assessed by flow cytometry as described in Materials and methods. As shown in Figure 1b , MK4 inhibited HL-60 cell growth in a dose-dependent manner. However, HL-60-bcl-2 cells were less sensitive as compared with HL-60-neo cells. (A concentration of 50% growth inhibition (IC 50 ) was 6 m for HL-60-neo and 14 m for HL-60-bcl-2, respectively). In addition, as previously reported in other leukemia cell lines and primary cultured leukemia cells, 3, 17 treatment with 10 m of MK4 for 72 h potently induced apoptosis of HL-60-neo cells as assessed by both morphology and flow cytometric analysis using APO2.7 mAb, an antibody which specifically detects the cells undergoing apoptosis. 17, 20 In contrast, this apoptosis induction by VK2 treatment was almost completely blocked in HL-60-bcl-2 cells (Figure 2a, b) . Not shown is that even though the concentration of MK4 was increased to 50 m, apoptotic induction was still not evident in HL-60-bcl-2 cells.
Evidence shows that the apoptotic process induced by various factors emerged in part to depolarize the mitochondrial membrane charge following cytochrome c release from the mitochondria into the cytosol, leading to activation of the caspase cascade.
22,23 Therefore, we next examined the change of the mitochondrial membrane potential and caspase-3 activity to investigate whether the apoptosis process, induced by VK2, mediates through this pathway. A 24 h exposure to 10 m of VK2 resulted in the depolarization of the mitochondrial membrane potential in HL-60-neo cells; however, it was significantly suppressed in HL-60-bcl-2 cells. In addition, caspase-3 was activated in response to VK2 in HL-60-neo cells, while its activation was almost completely blocked in VK2 treated HL-60-bcl-2 cells (Figures 3 and 4) . These data suggest that the VK2-induced apoptotic process mediates a rather common pathway as reported in various systems.
Inhibition of cell cycle progression in response to VK2 in HL-60 cells
It was noteworthy that, although apoptosis induction was almost completely suppressed, cell growth inhibition was still detectable at over 5 m of VK2 treatment in HL-60-bcl-2 cells (Figure 1b) . This suggested that VK2 treatment may also act as a cytostatic. To examine this hypothesis, we next performed cell cycle analysis using HL-60-bcl-2 cells. As shown in Figure 5 , the percentage of the cells in the G0/G1 phase was significantly increased from 67.2% to 85.3% in response to 48 h exposure to VK2 in HL-60-bcl-2. As described above, most HL-60-neo cells underwent apoptosis in response to VK2 ( Figure 5 , left panel: degradation of DNA is observed in a DNA histogram of HL-60-neo cells), however, G0/G1 arrest was still detectable when the gating area on the cytogram was focused on the surviving cells in flow cytometry (87.8% in the G0/G1 phase). In addition, the expression of the CDK inhibitor
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Figure 2
Over expression of BCL-2 protein abolishes VK2-induced apoptosis in HL-60 cells. HL-60-bcl-2 and HL-60-neo cells were treated with/without 10 m of MK4 for 72 h. (a) Morphologic features of HL-60 cells. May-Grü nwald-Giemsa staining. This is a reproducible result from one of three separate experiments (original magnification ×1000). (b) Apoptosis induction was quantitatively assessed by flow cytometry using APO2.7 mAb which specifically detects the cells undergoing apoptosis. Data are presented as the mean ± s.d. of triplicate determinations. This is a reproducible result from one of three separate experiments. (*P Ͻ 0.001 vs controls).
Figure 3
VK2 induces depolarization of the mitochondrial membrane potential in HL-60-neo but not in HL-60-bcl-2 cells. After treatment with/without 10 m of MK4 for 48 h, the mitochondrial membrane potential was assessed by flow cytometry using JC-1. Data are presented as the mean ± s.d. of triplicate determinations. (*P Ͻ 0.001; **P Ͻ 0.01 vs controls).
Figure 4
VK2 induces activation of caspase-3 in HL-60-neo, but not in HL-60-bcl-2 cells. After treatment with/without 10 m of MK4 for 72 h, caspase-3 activities in HL-60-neo and HL-60-bcl-2 cells were analyzed by flow cytometry using a substrate reagent kit which contains PhiPhiLUx-G6D2, a rhodamine-containing specific substrate. Data are present as the mean ± s.d. of triplicate determinations. This is a reproducible result from one of three separate experiments. (*P Ͻ 0.001 vs controls).
Figure 5
VK2 induces G0/G1 arrest in HL-60 cells. The cells were treated with 10 m of MK4 for 48 h, then the cell cycle analysis using flow cytometry was performed as described in Materials and methods. For the HL-60-neo cells which survived MK4 treatment, a gating area on a flow cytogram was established according to the forward and side scatter intensities and the cells were introduced to cell cycle analysis. This is a reproducible result from one of three separate experiments.
p27KIP1, but not p21CIP1, was up-regulated in HL-60-bcl-2 cells after treatment with VK2 ( Figure 6 ).
Induction of monocytic differentiation in HL-60 cells after treatment with VK2
It has been reported in various cell systems such as hematopoietic cells, glioma cells, and keratinocytes, [24] [25] [26] [27] [28] [29] that a cell cycle arrest in G0/G1 is one of the critical checkpoints for the cell to differentiate. We next examined whether VK-2 treatment induced cell differentiation in HL-60-bcl-2 cells in accordance with G0/G1 arrest. Condensation and the cleaving of nuclei of HL-60-bcl-2 were observed after a 72 h treatment with VK2. In addition, most HL-60-bcl-2 cells became positive for non-specific esterase in response to VK2 (Figure 7a, b) . Furthermore, flow cytometry revealed that enhanced expressions of CD14, CD15 and CD16 antigens were detected ( Table 1 ). These data demonstrate that treatment HL-60-bcl-2 cells with VK2 induces monocytic differentiation.
Discussion
In the present study, we have demonstrated that treatment with VK2 potently induced apoptosis in HL-60-neo cells, whereas in HL-60-bcl-2 cells this apoptosis induction was almost completely blocked by enforced overexpression of BCL-2, but that G0/G1 arrest and monocytic differentiation were still observed. This suggests that VK2 demonstrates not only apoptosis, but also differentiation induction against the leukemia cells which are resistant to VK2-inducing apoptosis. In addition, we have recently observed that in some cases of primary cultured leukemic cell clones, which were rather resistant to apoptosis induction in response to VK2 underwent differentiation in vitro (Funato and Miyazawa, manuscript in preparation). Vitamin K compounds contain a quinone group in their structure similar to some widely used antitumor agents, such as adriamycin and daunorubicin. The quinone group is involved in growth suppression and anti-tumor activity through the generation of free radicals and active oxygen species. 1 Therefore, it is not so surprising that these vitamin K compounds show some anti-leukemic activity. However, unlike these anti-tumor reagents, VK2 has a much lower toxicity and does not induce bone marrow suppression, [13] [14] [15] 30 which are important clinical benefits for the treatment of patients with MDS and AML.
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Considerable evidence shows that mitochondria play a central role in apoptosis (reviewed in Ref. 31) . Apoptotic processes are converged to the mitochondrial steps such as the release of the apoptogenic factor cytochrome c following the activation of caspase cascade. [32] [33] [34] Cytochrome c release into cytosol and the subsequent decrease of the mitochondrial inner membrane potential before the activation of caspase-3 has been reported to be blocked by BCL-2 in various systems. [35] [36] [37] In our study, along with almost complete suppression of VK2-induced apoptosis, both the depolarization of the mitochondrial membrane potential and caspase-3 activation were also concomitantly suppressed (Figures 3 and 4) . This suggests that mitochondria appear to be an important target organ for apoptosis by VK2, as well as by other apoptotic inducers. However, the signaling pathways leading to mitochondria have not been elucidated, though we have previously reported that treatment with an MDS cell line with VK2 induced up-regulation of BAX and down-regulation of BCL-2 protein expressions. 11 It was proposed that the nuclear binding protein for vitamin K2 exists in nuclei similar to other vitamin receptors and that the molecular structure is very close to that of human GAPDH. 38 However, so far, the specific receptor for VK2 is still not yet identified. It is also not clear whether this apoptosis induction by VK2 requires specific binding to the cognate receptor.
VK2 showed cytostatic effects by G0/G1 arrest on HL-60-bcl-2 cells, which were completely resistant to apoptosis induction, and induced monocytic differentiation (Figures 5  and 7 ). This suggests that induction of apoptosis via mitochon-Leukemia drial membrane instability and G0/G1 arrest appear to be mediated through the distinct pathways. However, cell cycle arrest and differentiation have been reported to be tightly linked processes. 39 Over-expression of p21CIP1 induces cell differentiation and G1 arrest in a human glioma cell line. 24 Retinoic acid-dependent growth arrest of the LAN-5 neuroblastoma cell line is associated with accumulation of p27KIP1 leading the cells to G1 arrest and induced terminal differentiation. 25 In U937 cells, treatment with 1,25(OH) 2 D 3 induced up-regulation of the gene expression of cyclin-dependent kinase inhibitors p21, p25, p15 and p18 during myeloid differentiation. 26 Furthermore, in normal human keratinocytes, the introduction of eta and delta isoforms of protein C lead to G1 arrest and differentiation. 27 Growth arrest in the G1 phase also resulted in the production of melanin in murine melanoma B16 cells after treatment with mannosylerythriol lipid. 28 All these lines of evidence suggest that G1 arrest has been the critical process during which the cell undergoes differentiation, although some reports argue that cycle arrest is part of a broader molecular program during differentiation, but is not enough by itself. 40, 41 Then one may ask whether a lower concentration of MK4 induces differentiation rather than apoptosis in HL-60-neo cells, as well as some anti-tumor reagents such as cytosine arabinoside (Ara-C); a higher concentration of Ara-C induces apoptosis of myeloid leukemia cells whereas a lower concentration induces leukemic cell differentiation. 42, 43 However, when we treated HL-60-neo cells with a lower concentration of MK4 (0.5 to 1 m), no change of cell surface antigen expression was observed (data not shown). This suggests that a concentration threshold for VK2 that induces biological response may exist, and also the interaction between VK2 and its cognate nuclear receptors may be required for the induction of a series of cellular responses. In our system, p27KIP1 but not p21CIP1 was up-regulated in response to VK2 (Figure 6 ). This was probably because the HL-60 cell line lacks p53, an inducer for p21CIP1 transcription. 44, 45 Considering the relation between apoptosis and differentiation, it is still possible that the suppression of apoptosis in HL-60-bcl-2 cells is due not only to the stabilization of mitochondrial membrane permeability by an over-expressed BCL-2 molecule, but also to the fact that the cell has undergone monocytic differentiation itself. Others have reported that, in U937 cells, subcellular localization of p21CIP1 has been changed from the nucleus to the cytosol along with monocytic differentiation in response to vitamin D 3 treatment, and this cytosolic p21CIP1 blocked apoptotic stimuli by binding to the stress-activated ASK1 and inhibiting its kinase activity. 46 The dichotomous nature of VK2 in leukemia cells appear to explain well the previous clinical observations in the patients with MDS and AML who were treated with VK2. In the patients with RAEB-T and post-MDS AML, VK2 has been reported to show a selective apoptosis induction of leukemic blasts cells in vitro, 17 to eliminate blastic cells and furthermore to improve cytopenia in vivo when the patients orally received 45 to 90 mg/day of MK4.
12, 13 Since hematological improvements were achieved without significant marrow suppression in some cases, the differentiation induction of the MDS clone in response to VK2 might also be involved. In addition, in a patient with RA, daily oral treatment of 45 mg of MK4 resulted in dramatic improvement of cytopenia, followed by becoming completely transfusion independent. 15 Improvement of cytopenias such as anemia and thrombocytopenia has also been reported in 20% of patients having RA, according to a retrospective clinical survey.
14 Since there were no adverse effects or bone marrow suppression, a differentiation inducing effect of VK2 on the MDS clone may be involved. 14 In addition, a combination of all-trans retinoic acid and VK2 succeeded in inducing complete hematological remission in a case of relapsed acute promyelocytic leukemia, probably because of the induction of leukemic cell differentiation. 30 K vitamins have been clinically used for the treatment of patients with a deficiency of the VK2-dependent coagulants. In addition, patients with osteoporosis have been treated with daily oral MK4 administration. 47 Therefore, the safety and non-toxicity of VK2 for long-term administration as a medicine has been well-established. The apoptosis-and differentiation-inducing effects of VK2 on leukemia cells shown in this paper will provide a novel strategy for treating leukemias and other hematopoietic malignancies. Further basic studies, especially for identification of the nuclear VK2 receptor and for intracellular responses of post receptor-VK2 binding will clarify the potency of VK2 for the management of hematological malignancies.
